Skip to content
everlon
Log inGet started

Learn

The July 2026 FDA peptide vote, explained

By the Everlon founding team ·

Quick answer On July 23 and 24, 2026, a committee of outside experts that advises FDA looked at seven peptides and, according to news reports, recommended that six of them be added to the list of ingredients compounding pharmacies may use. FDA's own staff had argued against all seven, and the committee only advises: it doesn't approve drugs or change the law. So as of October 2026 nothing has changed for patients, and licensed pharmacies still can't compound any of the six. The next thing to watch for is a proposed rule from FDA, which hadn't appeared when we checked.

What the committee is, and what it isn't

The Pharmacy Compounding Advisory Committee, usually shortened to PCAC, is a federal advisory committee of outside experts. It advises FDA on which bulk ingredients should go on the 503A bulks list: the list of substances a licensed compounding pharmacy may use when no approved drug and no official quality standard stands behind them.

It is advisory in the plain sense of the word. The committee does not make law, does not approve drugs, and its recommendations don't bind FDA. FDA's meeting page says advisory committees make non-binding recommendations, which FDA generally follows but is not legally required to follow. FDA announced this meeting in the Federal Register on April 16, 2026 and opened a public docket for comments.

What the committee did

FDA has not posted minutes, a roll call, a transcript or vote results for this meeting; its meeting page was last updated on August 6, 2026 and still showed none when we checked in October. The outcomes below come from news reports (STAT, July 24, 2026; CNN and AJMC, July 31, 2026), which agree on every one. This page prints no vote counts, because FDA has published none.

PeptideDayUse FDA reviewed (per FDA's meeting page)Outcome, as reported
BPC-157July 23Ulcerative colitisRecommended
KPVJuly 23Wound-related uses and inflammatory conditionsRecommended
TB-500July 23Wound-related usesRecommended
MOTS-cJuly 23Obesity and osteoporosisRecommended
SemaxJuly 24Cerebral ischemia, migraine and trigeminal neuralgiaRecommended
EpitalonJuly 24InsomniaRecommended
DSIP (emideltide)July 24Opioid withdrawal, chronic insomnia and narcolepsyNot recommended

Each substance was considered in two forms, the free base and the acetate salt, and FDA's voting questions asked about each form separately; the news reports give one result per substance. Don't read a recommendation as a verdict on any one use: FDA's briefing notes that a listing may not be limited to a specific use, and the committee voted on a compounding list, not on whether anything is safe or works.

The seven peptides, one by one

A short, neutral note on each, with a link to its own page where one exists.

BPC-157

A lab-made peptide of 15 amino acids, first described as a fragment of a protein from human gastric juice. FDA reviewed it for ulcerative colitis and its staff proposed against listing it; the committee recommended it, per the news reports above. As of October 2026 it is not FDA-approved and not on the bulks list. Is BPC-157 legal or FDA approved? has the full status, and BPC-157 vs TB-500 compares it with the peptide it is most often paired with.

KPV

A three-amino-acid fragment of alpha-MSH, a hormone the body makes. FDA reviewed it as a cream or gel for wound-related uses and inflammatory skin conditions, found no study of it in people, and proposed against listing it; the committee recommended it. Not FDA-approved and not on the bulks list as of October 2026. What is the KPV peptide?

TB-500

A lab-made, seven-amino-acid fragment of the natural protein thymosin beta-4, which FDA's reviewers say is not the same substance as the full protein. FDA reviewed it for wound-related uses by injection, found no study in people, and proposed against listing it; the committee recommended it. Not FDA-approved and not on the bulks list as of October 2026. What is TB-500?

MOTS-c

A 16-amino-acid peptide encoded in mitochondrial DNA. FDA reviewed it for obesity and osteoporosis, found no published study of it given to people, and proposed against listing it; the committee recommended it. Not FDA-approved and not on the bulks list as of October 2026. What is MOTS-c?

Semax

A lab-made peptide built from a fragment of the pituitary hormone ACTH, registered as a drug in Russia according to FDA's briefing and not approved in the United States. FDA reviewed it for cerebral ischemia, migraine and trigeminal neuralgia and proposed against listing it; the committee recommended it. Not on the bulks list as of October 2026. What is Semax?

Epitalon

A lab-made peptide of four amino acids, reviewed by FDA for insomnia and recommended by the committee per the news reports; as of October 2026 it is not FDA-approved and not on the bulks list.

DSIP (emideltide)

A peptide FDA reviewed for opioid withdrawal, chronic insomnia and narcolepsy. News reports say the committee did not recommend it, the one substance of the seven it turned down. That creates no new prohibition; it means the committee did not back adding it. It matters because it shows the committee voted substance by substance, and because nothing decided about the other six says anything about a peptide that was not on this agenda.

Why FDA's own reviewers said no

FDA's briefing documents proposed that none of the seven be added to the bulks list. For each one, the reviewers concluded that FDA's four evaluation criteria (how well the substance is characterized, what is known about its safety, the evidence on effectiveness for the nominated use, and its history of use in compounding) weigh against listing it. For all seven, the companies that had nominated the substance had withdrawn their nominations earlier in 2026, and FDA chose to bring them to the committee anyway. A favorable vote against staff advice is a weaker signal than a favorable vote with it, and FDA is not bound by either.

What changed after the vote

For anyone prescribing or dispensing, nothing:

  • the 503A bulks list was not amended, and it is a federal regulation that only notice-and-comment rulemaking can change;
  • none of the six became lawful to compound, so licensed pharmacies can't compound them yet;
  • none of them is an FDA-approved drug;
  • none of them moved into Category 1, FDA's interim "we don't intend to act" category, or into either of FDA's other two categories. How the categories work.

The recommendations feed a rulemaking process that had not started as of October 6, 2026: a Federal Register search that day found no proposed rule for any of the six. FDA has announced a second meeting, before the end of February 2027, on five other substances (LL-37, injectable GHK-Cu, dihexa, Melanotan II and PEG-MGF). It is a separate proceeding, and nothing decided in July carries into it.

Is this right for me?

This page is for anyone who read that FDA "approved peptides" and wants to know what actually happened. It can't tell you whether any treatment suits your health; only a licensed provider who knows your history can, and the answer may be no.

What you can do now:

  • Read the page for the peptide you came here about; each one above links to it.
  • If a clinic or website offers one of the six, ask on what legal basis, given that none is on the bulks list. How to get peptides legally explains the difference between a prescription and a "research use only" label.
  • Take the goal that brought you here to your own doctor.
  • If you want to hear whether availability changes, use the sign-up at the end of this page. It reserves nothing.

How it works

  1. Enter your email below. The form at the end of this page asks for your email address and state, and nothing about your health.
  2. Hear from us only if something becomes available through a licensed provider. We write about availability and nothing else, and you can unsubscribe anytime.
  3. A licensed provider still decides. Being on the list is not a reservation or a prescription. If FDA's rules change, a provider licensed in your state reviews your health history first and can decline.

FAQ

Which peptides did FDA approve in July 2026? None. FDA approved nothing. An advisory committee recommended six of seven peptides for the compounding bulks list, according to news reports, and FDA has not acted on the recommendations. Being on the bulks list would not make a substance an approved drug in any case.

Does this mean a pharmacy can compound BPC-157 now? No. The bulks list was not amended, so licensed pharmacies can't compound it. The status explainer is here.

Does FDA usually follow the committee? FDA says it generally follows advisory committee recommendations but is not legally bound to. Here FDA's own reviewers proposed the opposite, and FDA has announced no timetable, so the outcome is hard to predict.

How many votes did each peptide get? FDA has not posted a vote record, so this page prints no counts. The outcomes above are as reported by STAT, CNN and AJMC.

What should I watch for next? A proposed rule in the Federal Register, with a docket number and a comment deadline. Until that document exists there is no timeline to follow, and any date you see online is a guess.

What this means for you

As of October 2026, licensed pharmacies can't legally compound any of the six peptides for patients: none is on FDA's 503A bulks list, and only FDA rulemaking changes that. If FDA lists them one day, the legal route would be a prescription from a licensed provider in your state, filled by a licensed pharmacy; compounded medications are not FDA-approved. Until then, products sold online as "research use only" aren't made for people.

Safety information

None of the seven substances the committee reviewed is an FDA-approved drug, and no licensed pharmacy can compound any of the six that were recommended, so there is no FDA-approved, labeled product to describe here.

  • What FDA has said. FDA's page on substances that may present significant safety risks says, for several of these peptides, that compounded drugs may pose a risk of immunogenicity (an immune reaction to the peptide), may have complexities with peptide-related impurities, and that FDA lacks the information to know whether the drug would cause harm when given to people. Each peptide's own page quotes FDA's statement about it word for word.
  • Not a verdict either way. Those statements are not a finding that any of them is harmful, and not a finding that any of them is safe.
  • "Research use only" products. They are not prepared by a licensed pharmacy for a named patient, no prescriber reviews your health history, and nothing assures you of what is in them. Everlon never sells "research use only" products.
  • Compounded medicines in general. Compounded medications are not FDA-approved, which would remain true even if a licensed pharmacy could one day prepare one of these substances.

If you have used a product sold under one of these names and something feels wrong, stop and contact a doctor; you can also report it to FDA's MedWatch program. If this is a medical emergency, call 911.

Sources

Where to go next

All guidesHow it worksWhere we serve

Compounded medications are prepared by a state-licensed 503A compounding pharmacy and are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed.

Individual results vary. Treatment is prescribed only when clinically appropriate, and a prescription is never guaranteed. This article is for education and is not a substitute for professional medical advice, diagnosis, or treatment. If this is a medical emergency, call 911.

We use cookies to keep our site working and make it better. We never share your name or health answers. Tap OK to allow them, or Manage cookies to choose.